$TAK

Greenway Nicola Deidre Petal sold $606K of TAK

Greenway Nicola Deidre Petal (Chief Human Resources Officer) sold 34,603 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at an average of $17.51 ($17.50–$17.51, $0.61M total) across 2 trades on 2026-08-10.

Original reporting
SEC EDGAR · Greenway Nicola Deidre Petal
Published Aug 12, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TAK
Neutral
medium confidence
Mentioned
$TAK
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale amount, price range, and post-transaction holdings; it may slightly influence short-term sentiment but does not constitute new company guidance or events.

02

Market read

A routine insider sale by a senior executive is disclosed, with no accompanying fundamental catalyst in the text.

03

What to watch

The article does not provide context on total compensation, prior sale history, or whether other insiders sold/bought around the same time, limiting inference.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-12, transaction dated 2026-08-10

Background

The article is a SEC Form 4 insider transaction disclosure for Takeda, reported via SEC EDGAR.

Company-level read

Ticker impact

$TAKNeutralMedium confidence
Context

Takeda (TAK) is the Form 4 issuer, showing CFO Greenway Nicola Deidre Petal sold 34,603 shares at about $17.51 on 2026-08-10.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless accompanied by other disclosures.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan stated and no accompanying company-specific operational or financial update in the text.

Market effects

Insider selling in large pharma is usually not sector-moving absent broader guidance or regulatory/clinical catalysts.

None indicated.

None indicated.

Counterpoint

The sale could be driven by diversification, taxes, or pre-planned liquidity needs rather than a negative view on Takeda’s prospects.

Key entities

  • Takeda Pharmaceutical Co Ltd

    Subject of the Form 4 insider transaction disclosure.

  • Greenway Nicola Deidre Petal

    Chief Human Resources Officer who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TAKMedAI 9/10

Why Zasocitinib Outperformed Deucravacitinib in New Plaque Psoriasis Data

Zasocitinib, an investigational TYK2 inhibitor by Takeda, showed superior efficacy in treating plaque psoriasis compared to deucravacitinib in a phase 3 trial. 36.5% of patients achieved PASI 100 with zasocitinib vs. 13.9% with deucravacitinib. The drug's higher TYK2 selectivity and longer IL-23 blockade were cited as key factors. Zasocitinib is under review by the FDA and EMA.

$TAKHighAI 9/10

Oveporexton Improves Wakefulness and Cataplexy in Narcolepsy Type 1

Takeda's Oveporexton (Orzeyful) significantly improved wakefulness, daytime sleepiness, and cataplexy in narcolepsy type 1 patients over 12 weeks, according to two phase 3 trials. The FDA approved the drug in August 2026, positioning it as the first therapy addressing orexin deficiency. Adverse events included increased urinary frequency and transient insomnia. Trials showed mean sleep latency improvements of 14.3 to 19.8 minutes with Oveporexton vs. placebo.

$TAKMedAI 8/10

Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

Takeda announced Phase 3 trial results showing zasocitinib (TAK-279) demonstrated superior efficacy in treating moderate-to-severe plaque psoriasis compared to deucravacitinib. Key data: 36.5% of patients achieved complete skin clearance (PASI 100) at week 16 vs. 13.9% for deucravacitinib. Zasocitinib also showed durable skin clearance and improvements in itch and quality of life. The drug is under regulatory review for psoriasis treatment.

$TAKMedAI 9/10

Takeda Pharmaceutical Company Limited: Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

Takeda (TSE:4502/NYSE:TAK) will present data on its oncology pipeline at ESMO 2026, including Phase 3 results for arcotatug tavatecan in advanced gastric cancer and findings on TAK-928 for NSCLC. The company is expanding a global Phase 3 study for TAK-928.